7 results on '"Qin, Xinyu"'
Search Results
2. The prognostic value of CXC-chemokine receptor 2 (CXCR2) in gastric cancer patients.
- Author
-
Zhenglin Wang, Hao Liu, Zhenbin Shen, Xuefei Wang, Heng Zhang, Jing Qin, Jiejie Xu, Yihong Sun, Xinyu Qin, Wang, Zhenglin, Liu, Hao, Shen, Zhenbin, Wang, Xuefei, Zhang, Heng, Qin, Jing, Xu, Jiejie, Sun, Yihong, and Qin, Xinyu
- Subjects
STOMACH cancer patients ,CHEMOKINE receptors ,STOMACH cancer ,CANCER cell proliferation ,IMMUNOHISTOCHEMISTRY ,HEALTH outcome assessment ,PROGNOSIS ,CANCER-related mortality ,CANCER ,CELL receptors ,CYTOPLASM ,METASTASIS ,MULTIVARIATE analysis ,STOMACH tumors ,PREDICTIVE tests ,RETROSPECTIVE studies ,KAPLAN-Meier estimator - Abstract
Background: CXC chemokine receptor 2 (CXCR2) has been reported to play an important role in the proliferation and invasion of gastric cancer cells. The present study aims to investigate the impact of CXCR2 expression on the overall survival (OS) of gastric cancer patients after radical resection.Methods: Intratumoral CXCR2 expression was evaluated with immunohistochemistry on tissue microarrays containing tumor samples of 357 gastric cancer patients from a single center. CXCR2 expression levels were correlated to clinicopathological variables and OS.Results: CXCR2 expression was mainly located in the cytoplasm of gastric carcinoma cells. High CXCR2 expression was associated with poor tumor differentiation (p = 0.021), increased tumor depth (p < 0.001), lymph node metastasis (p < 0.001), advanced TNM stage (p < 0.001) and short OS (p = 0.001). CXCR2 expression was an independent prognostic factor for OS (p = 0.001) in multivariate analysis, and could be combined with TNM stage to generate a predictive nomogram for clinical outcome in patients with gastric cancer.Conclusion: Intratumoral CXCR2 expression is a novel independent predictor for survival in gastric cancer patients. CXCR2 might be a promising therapeutic target of postoperative adjuvant treatment. [ABSTRACT FROM AUTHOR]- Published
- 2015
- Full Text
- View/download PDF
3. Induction of protective and therapeutic anti-pancreatic cancer immunity using a reconstructed MUC1 DNA vaccine.
- Author
-
Rong Y, Jin D, Wu W, Lou W, Wang D, Kuang T, Ni X, Qin X, Rong, Yefei, Jin, Dayong, Wu, Wenchuan, Lou, Wenhui, Wang, Danshong, Kuang, Tiantao, Ni, Xiaoling, and Qin, Xinyu
- Abstract
Background: Pancreatic cancer is a common, highly lethal disease with a rising incidence. MUC1 is a tumor-associated antigen that is over-expressed in pancreatic adenocarcinoma. Active immunotherapy that targets MUC1 could have great treatment value. Here we investigated the preventive and therapeutic effect of a MUC1 DNA vaccine on the pancreatic cancer.Methods: MUC1-various tandem repeat units(VNTR) DNA vaccine was produced by cloning one repeat of VNTR and inserting the cloned gene into the pcDNA3.1. In the preventive group, female C57BL/6 mice were immunized with the vaccine, pcDNA3.1 or PBS; and challenged with panc02-MUC1 or panc02 cell. In the therapeutic group the mice were challenged with panc02-MUC1 or panc02 cell, and then immunized with the vaccine, pcDNA3.1 or PBS. The tumor size and the survival time of the animals were compared between these groups.Results: The DNA vaccine pcDNA3.1-VNTR could raise cytotoxic T lymphocyte (CTL) activity specific for MUC1. In the preventive experiment, the mice survival time was significantly longer in the vaccine group than in the control groups (P < 0.05). In the therapeutic experiment, the DNA vaccine prolonged the survival time of the panc02-MUC1-bearing mice (P < 0.05). In both the preventive and therapeutic experiments, the tumor size was significantly less in the vaccine group than in the control groups (P < 0.05). This pcDNA3.1-VNTR vaccine, however, could not prevent the mice attacked by panc02 cells and had no therapeutic effect on the mice attacked by panc02 cells.Conclusion: The MUC1 DNA vaccine pcDNA3.1-VNTR could induce a significant MUC1-specific CTL response; and had both prophylactic and therapeutic effect on panc02-MUC1 tumors. This vaccine might be used as a new adjuvant strategy against pancreatic cancer. [ABSTRACT FROM AUTHOR]- Published
- 2009
- Full Text
- View/download PDF
4. The IGCA staging system is more accurate than AJCC7 system in stratifying survival of patients with gastric cancer in stage III.
- Author
-
Shu P, Qin J, Shen K, Chen W, Liu F, Fang Y, Wang X, Wang H, Shen Z, Sun Y, and Qin X
- Subjects
- Adult, Aged, Aged, 80 and over, Female, Follow-Up Studies, Humans, Male, Middle Aged, Prognosis, Retrospective Studies, Stomach Neoplasms classification, Survival Rate, Young Adult, Neoplasm Staging standards, Stomach Neoplasms mortality, Stomach Neoplasms pathology
- Abstract
Background: A new staging system recently proposed by the IGCA has demonstrated a better capacity of stratifying different prognoses for gastric cancer than the 7th edition AJCC staging system (AJCC7). The aim of this study was to evaluate the efficacy of the IGCA system in Chinese patients., Methods: Medical records of patients with gastric cancer who received curative surgery in our center from January 2003 to December 2011 were reviewed retrospectively. All the lesions were staged according to both AJCC7 and IGCA staging systems. Overall survival (OS) of the patients was used as the observation endpoint., Results: One thousand five hundred twenty-six cases were included in this study. By comparing the AJCC7 system with the IGCA systems, 395 cases were stratified into different stages, most of which were in stage III. The IGCA system could better stratify stage IIIB and IIIC patients (5-year OS, 38.1% vs. 29.0%; P = 0.005) than the AJCC7 system (5-year OS, 38.2% vs. 35.9%; P = 0.148). T3N3bM0, T4aN2M0 and T4aN3bM0 made up 97.5% (385/395) of the stage shift. T3N3bM0, which was stratified to stage IIIB in the AJCC7 system, showed a significant poorer prognosis than T4aN2M0 and T4aN3aM0, which were staged to IIIB and IIIC in the same system. The improper staging was revised in the IGCA staging system., Conclusions: The IGCA staging system can stratify stage III gastric cancer patients more properly than the AJCC7 system.
- Published
- 2017
- Full Text
- View/download PDF
5. Expert consensus on robotic surgery for colorectal cancer (2015 edition).
- Author
-
Xu J and Qin X
- Subjects
- Colectomy, Consensus, Humans, Practice Guidelines as Topic, Colorectal Neoplasms surgery, Robotic Surgical Procedures methods
- Published
- 2016
- Full Text
- View/download PDF
6. The prognostic value of CXC-chemokine receptor 2 (CXCR2) in gastric cancer patients.
- Author
-
Wang Z, Liu H, Shen Z, Wang X, Zhang H, Qin J, Xu J, Sun Y, and Qin X
- Subjects
- Adult, Aged, Carcinoma mortality, Carcinoma pathology, Cytoplasm metabolism, Female, Humans, Immunohistochemistry, Kaplan-Meier Estimate, Lymphatic Metastasis, Male, Middle Aged, Multivariate Analysis, Predictive Value of Tests, Prognosis, Retrospective Studies, Stomach Neoplasms mortality, Stomach Neoplasms pathology, Biomarkers, Tumor metabolism, Carcinoma metabolism, Receptors, Interleukin-8B metabolism, Stomach Neoplasms metabolism
- Abstract
Background: CXC chemokine receptor 2 (CXCR2) has been reported to play an important role in the proliferation and invasion of gastric cancer cells. The present study aims to investigate the impact of CXCR2 expression on the overall survival (OS) of gastric cancer patients after radical resection., Methods: Intratumoral CXCR2 expression was evaluated with immunohistochemistry on tissue microarrays containing tumor samples of 357 gastric cancer patients from a single center. CXCR2 expression levels were correlated to clinicopathological variables and OS., Results: CXCR2 expression was mainly located in the cytoplasm of gastric carcinoma cells. High CXCR2 expression was associated with poor tumor differentiation (p = 0.021), increased tumor depth (p < 0.001), lymph node metastasis (p < 0.001), advanced TNM stage (p < 0.001) and short OS (p = 0.001). CXCR2 expression was an independent prognostic factor for OS (p = 0.001) in multivariate analysis, and could be combined with TNM stage to generate a predictive nomogram for clinical outcome in patients with gastric cancer., Conclusion: Intratumoral CXCR2 expression is a novel independent predictor for survival in gastric cancer patients. CXCR2 might be a promising therapeutic target of postoperative adjuvant treatment.
- Published
- 2015
- Full Text
- View/download PDF
7. Oncolytic adenovirus armed with IL-24 inhibits the growth of breast cancer in vitro and in vivo.
- Author
-
Zhu W, Wei L, Zhang H, Chen J, and Qin X
- Subjects
- Adenoviridae, Animals, Apoptosis genetics, Cell Proliferation, Female, Genetic Vectors, Humans, Mice, Mice, Nude, Xenograft Model Antitumor Assays, Breast Neoplasms genetics, Breast Neoplasms metabolism, Interleukins administration & dosage, Interleukins genetics, Interleukins metabolism, Oncolytic Virotherapy, Oncolytic Viruses genetics, Recombinant Proteins administration & dosage, Recombinant Proteins genetics, Recombinant Proteins metabolism
- Abstract
Background: Interleukin-24 (IL-24) is a cytokine that belongs to the IL-10 family. It can selectively induce cancer cell apoptosis which has been utilized as a cancer gene therapy strategy., Methods: A recombinant type five adenovirus containing IL-24 gene (designated CNHK600-IL24) was constructed, whose replication is activated only in tumor cells. The replication of CNHK600-IL24 in breast tumor cells and fibroblasts were assessed by TCID50 and MTT assay; the secretion of IL-24 was measured by ELISA and western blotting. The in vivo anti-tumor effect of CNHK600-IL24 was investigated in nude mice carrying orthotopic or metastatic breast tumor., Results: We observed that CNHK600-IL24 could replicate efficiently and resulted in high level IL-24 expression and massive cell death in human breast cancer cell MDA-MB-231 but not in normal fibroblast cell MRC-5. In addition, orthotopic breast tumor growth in the nude mice model was significantly suppressed when CNHK600-IL24 was administered. In the metastatic model generated by tail vein injection, CNHK600-IL24 virotherapy significantly improved survival compared with the same virus expressing EGFP (median survival CNHK600-IL24, 55 days vs. CNHK600-EGFP, 41 day, p < 0.05 Mantal-Cox test). A similar phenomenon was observed in the metastatic model achieved by left ventricular injection as suggested by in vivo luminescence imaging of tumor growth., Conclusion: The oncolytic adenovirus armed with IL-24, which exhibited enhanced anti-tumor activity and improved survival, is a promising candidate for virotherapy of breast cancer.
- Published
- 2012
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.